Sept 12, 2006, © 2006 The Associated Press

Mylan Gets FDA OK on Generic Topamax Drug

PITTSBURGH — Pharmaceutical company Mylan Laboratories Inc. said Tuesday it received regulatory approval for a generic version of epileptic seizure treatment Topamax, making it the first challenger for the drug’s $1.37 billion U.S. market.

More here.

It’ll be interesting to see how long this takes and how much the generic will cost. Currently, Ortho-McNeil’s topiramate runs anywhere from $160 to $300 per month for a 200 mg daily dose. Info gathered from both legit and “no Rx required” sites.

This entry was posted on Wednesday, September 13th, 2006 at 11:00 am and is filed under Medications and research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.